Keywords: panel, backs, hivid, monotherapy, hoffmann-la, roche, reverse
US PANEL BACKS HIVID AS MONOTHERAPY...
Article | 04 October 1993
Hoffmann-La Roche's reverse transcriptase inhibitor Hivid (zalcitabine) is equivalent to Bristol-Myers Squibb's Videx (didanosine) as a treatment for HIV infection, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
